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Condensation: A program providing counseling and no-cost contraception yields substantial 
cost savings due to increased uptake of highly effective contraception and averted unintended 
pregnancy and birth. 
 
Short title: CHOICE Cost Savings Analysis 
 
AJOG at a Glance:  
A. We conducted this cost savings analysis to estimate the cost savings to Missouri 
Medicaid due to the high uptake of intrauterine devices and implants in the Contraceptive 
CHOICE Project and subsequent unintended pregnancies averted.  
B. In this cost savings analysis of 5,061 reproductive-age women provided with no-cost 
contraception, Missouri Medicaid saved an estimated $5.0 million due to 483 unintended 
births averted. 
C. These results provide important data about the public cost savings that may result from 
the increased uptake of intrauterine devices and implants. These data have implications 
for broader policies aimed at reducing unintended pregnancies as well as healthcare costs.  
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Abstract 
Background: Forty-five percent of U.S. births are unintended, and the costs of unintended 
pregnancy and birth are substantial. Clinical and policy interventions that increase access to the 
most effective reversible contraceptive methods, intrauterine devices and contraceptive implants, 
have potential to generate significant cost savings. Evidence of cost savings for these 
interventions is needed.  
Objective: To conduct a cost savings analysis of the Contraceptive CHOICE Project, which 
provided counseling and no-cost conception, to demonstrate the value of investment in enhanced 
contraceptive care to the Missouri Medicaid program. 
Study Design: The CHOICE Project was a prospective cohort study of 9,256 reproductive-age 
women, enrolled between 2007 and 2011 and followed until October 2013. This analysis 
includes 5,061 CHOICE Project participants who were current Missouri Medicaid beneficiaries 
or uninsured and reported household incomes less than 201% of the federal poverty line. We 
created a simulated comparison group of women receiving care through the Missouri Title X 
program and modeled the contraception and pregnancy outcomes that would have occurred in 
the absence of the CHOICE Project. Data about contraceptive use for the comparison group 
(N=5,061) were obtained from the Missouri Title X program and adjusted based on age, race, 
ethnicity, and income. To make an accurate comparison accounting for difference in the two 
populations, we used our simulation model to estimate total CHOICE Project costs and total 
comparison group costs. We reported all costs in $2013 to account for inflation. 
Results: Among the CHOICE Project participants included, the uptake of intrauterine devices 
and implants was 76.1% compared to 4.8% among the comparison group. The estimated 
contraceptive cost for the simulated CHOICE Project group was $4.0 million versus $2.3 million 
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for the comparison group. The estimated numbers of unintended pregnancies and births averted 
among the simulated CHOICE Project group compared to the comparison group were 927 and 
483 respectively, representing a savings in pregnancy and maternity care of $6.7 million.  We 
estimated that the total cost savings for the state of Missouri attributable to the CHOICE Project 
was $5.0 million (40.7%) over the project duration.   
Conclusions: A program providing counseling and no-cost contraception yields substantial cost 
savings due to increased uptake of highly effective contraception and consequent averted 
unintended pregnancy and birth. 
 
Key Words: contraceptive counseling, contraceptive implant, cost savings analysis, intrauterine 
device, long-acting reversible contraception, return on investment  
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Introduction  
Unintended pregnancy carries significant public health costs including reduced maternal 
quality of life, adverse maternal behaviors, and poorer infant outcomes.1,2 Societal costs are also 
large, including reduced educational attainment, employment opportunities, and economic 
stability as well as greater dependence on public assistance.3 The economic costs of unintended 
pregnancy and birth are substantial, and U.S. taxpayers pay roughly $11 billion each year in 
costs associated with unintended pregnancy.4 
The Contraceptive CHOICE Project was a prospective study of 9,256 reproductive-age 
women that provided comprehensive contraceptive counseling, no-cost contraception, and 
reduced barriers to reversible contraception. These barriers included provider misconceptions,5 
high out-of-pocket cost, 6 and multiple visits requirements for initiation of long-acting reversible 
contraception (LARC; intrauterine devices (IUDs) and implants).7,8 CHOICE participants had a 
high uptake of LARC and subsequent reductions in unintended and teen pregnancy.9,10 Multiple 
studies have demonstrated that provision of contraception, including LARC, results in economic 
savings.11,12 One cost effectiveness analysis found that although LARC is associated with higher 
upfront costs, these methods generate cost savings after approximately two years of use.13  
The objective of this analysis was to estimate the cost savings the CHOICE Project 
contributed to the Missouri Medicaid program over the study period. Our secondary objective 
was to estimate potential public cost savings if the CHOICE Project model were scaled up to 
Missouri Medicaid beneficiaries statewide. 
 
Materials and Methods 
Model design and population  
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Participants in the Contraceptive CHOICE Project were enrolled between 2007 and 2011 
and followed for two or three years through October 2013.14 Inclusion criteria for the CHOICE 
Project included age 14–45 years, not currently using a reversible contraceptive method or 
willing to start a new method, did not desire pregnancy for the next 12 months, sexually active 
with a male partner, and resided in the St. Louis area. We limited inclusion in this analysis to 
women who reported receipt of Medicaid or had incomes less than 201% of the federal poverty 
level (FPL), which is the income eligibility threshold for Missouri’s family planning waiver 
program, the Women’s Health Services Program (MO-WHSP), as well as pregnancy-related 
Medicaid. The time horizon for the analysis was 45 months which included the 36-month study 
period plus an additional 9 months to account for any births resulting from conception that 
occurred during the study period.   
To create a comparison group for the analysis, we estimated the contraceptive method 
distribution that women would have selected in the absence of the CHOICE Project.  We used 
data regarding the contraceptive method chosen by women receiving care at Missouri health 
centers participating in the Title X program between 2008 and 2012. Women who were currently 
pregnant, seeking pregnancy, or had a prior sterilization were excluded, as they were from the 
CHOICE Project. Given the demographic differences between the CHOICE cohort and the Title 
X program participants (shown in Table 1), we used multinomial logistic regression to obtain 
probabilities that a CHOICE participant, in the absence of the study intervention, would have 
selected each method. Contraceptive outcomes were categorized as follows: (1) IUD or implant; 
(2) injectable contraception; (3) oral contraceptive pills (OCPs), contraceptive patch, or vaginal 
ring; (4) condoms, other barriers methods, withdrawal, or fertility awareness; and (5) no method. 
Adjustment was limited to four demographic characteristics due to the available MO Title X 
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data: age (19 years and under, 20-29, and 30 and above), race (white, black, and other race), 
Hispanic identity (non-Hispanic and Hispanic), and federal poverty level (less than 101% of the 
FPL and 101-200% of the FPL). This group formed the basis for a counterfactual simulation of 
the actual CHOICE participants’ experience in the absence of the CHOICE Project, thereby 
creating a comparison group with the CHOICE participant demographics but whose 
contraceptive choices were based upon the MO Title X population. 
For each woman in the comparison group, we conducted a Monte Carol simulation of 
outcomes and associated costs by executing 1,000 draws from the contraceptive distribution 
given by evaluating the multinomial logistic regression equation using the CHOICE participant’s 
specific demographic profile.  For each draw, we simulated the month-to-month occurrence of 
pregnancy as well as all possible outcomes (using assumptions discussed in detail below) and 
tallied associated costs, averaged over 1,000 draws to smooth cost estimates.  This generated two 
sets of simulated results: (1) those for the CHOICE population as predicted by our simulation, 
and (2) those for the comparison group. The simulated results for the CHOICE Project helped to 
test the accuracy and reasonableness of the assumptions entered into the simulation. All analyses 
were performed in SAS 9.4 (SAS Institute, Cary, NC) and STATA 14 (StataCorp, College 
Station, TX). 
Utilization of contraceptive methods 
For CHOICE participants, the assigned contraceptive method was the method chosen by 
the participant at study enrollment. For the comparison group, the method was assigned 
probabilistically using the MO Title X health center data described above. Methods were 
grouped into five the same contraceptive categories described above. To account for 
contraceptive discontinuation among women who chose an IUD or implant at baseline, we used 
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published CHOICE Project continuation rates at one year and two years using a linear trend to 
estimate monthly continuation rates.15 In case of discontinuation, we assumed the same 
contraceptive distribution as the comparison group at baseline. 
Costs of contraceptive methods 
To estimate the contraceptive costs across both the CHOICE and comparison 
populations, we used Missouri Medicaid reimbursement rates for IUDs, implants, and injectable 
contraception, and the retail acquisition costs for OCPs, patch, and ring for years 2007 through 
2011. These method-specific costs were incorporated into the simulation each time a particular 
method was drawn. Sensitivity of our results to these values was assessed by running the 
simulation using annual averaged contraceptive costs estimated by Laliberte et al which used 
Medicaid claims data for 11 million women across multiple states (including Missouri) between 
2004 and 2010.16 Using the averaged contraceptive costs showed minimal difference in the 
estimated cost savings. See Supplementary Materials for sensitivity analysis results. 
Cost of contraceptive initiation  
Because the CHOICE Project involved additional programmatic costs due primarily to 
provision of evidence-based, comprehensive contraceptive counseling by trained non-clinician 
counselors, we computed the cost of contraceptive initiation using actual costs from the CHOICE 
Project.  Annual salaries and fringe benefits for a full-time nurse practitioner, a half-time 
registered nurse, and a full-time contraceptive counselor were averaged over the number of 
CHOICE participants to approximate cost depending on enrollment year. We added 30% to the 
cost of salaries to account for overhead costs such as rent, utilities, and supplies.17 Since 
approximately twice the clinician time is required for LARC insertion, the per-participant nurse 
practitioner cost was calculated as a weighted average, with visits including LARC insertion 
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weighted twice as much as those for non-LARC methods. For IUDs and implants, method and 
initiation costs were assumed to occur in year 1 only as the maximum duration of study 
participation was 3 years, therefore, no method replacement due to expiration was necessary. 
Contraceptive initiation costs for the comparison group were estimated using Missouri 
Medicaid reimbursement rates. The estimated cost of initiation of OCPs, patch, ring, and 
injectable methods was the reimbursement amount for a new patient Level III office visit with a 
clinician. For initiation costs of IUDs and implant, the reimbursement for a new patient Level III 
and the method insertion were summed with the weighted by the percent of individuals who 
chose each type of IUD or the implant. We also calculated CHOICE Project costs using these 
rates within our simulation in order to capture the likely cost of a large-scale version of the 
project. See Supplementary Materials Tables 1A-3A for a summary of costs and supporting data 
sources. 
Costs of unintended pregnancy-related events 
In order to determine the number of unintended pregnancies, we incorporated previously 
published “typical use” contraceptive failure rates into the simulation model.18 The simulated 
CHOICE Project unintended pregnancy and birth outcomes were calibrated to exactly match the 
actual number of unintended pregnancies and births observed in the CHOICE Project.  This 
calibration occurred within the bounds of parameter ranges suggested by the literature and was 
chosen deliberately to ensure that the cost calculations would be accurate for the actual CHOICE 
Project.  
Five possible outcomes for unintended pregnancy were considered: live birth, induced 
abortion covered by Medicaid, induced abortion not covered by Medicaid, miscarriage, and 
ectopic pregnancy. We used a combination of CHOICE Project data as well as 2010 estimates 
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for the percentages of unintended pregnancies that result in live birth, miscarriage, or abortion in 
Missouri.19 Additional detail is provided in the Supplementary Materials.  The percent of 
pregnancies ending in an ectopic pregnancy was assumed using methods described by Trussell et 
al and subtracted from the miscarriage rate.13 The majority of induced abortions were assumed to 
have zero cost to the state, as Missouri Medicaid does not cover abortion except in cases of 
maternal life endangerment, rape, and incest. We estimated these to account for approximately 
one percent of induced abortions.20 Based upon this fact, we separated induced abortions into 
two categories: abortions covered by Missouri Medicaid and abortions not covered by Missouri 
Medicaid. 
Costs associated with birth outcomes were drawn from multiple sources.  We used data 
for the cost of birth and first year of life to Missouri Medicaid for fiscal years 2009 through 2011 
which was obtained from Missouri’s Evaluations of the MO-WHSP from 2011 and 2012.21,22 
The costs for miscarriage, induced abortions covered by Medicaid, and ectopic pregnancy were 
estimated using statistics reported by Trussell et al.13 
All costs were adjusted to 2013 dollars for the final estimates to account for inflation. We 
did not discount costs as the cost savings analysis was conducted from a state budgetary 
perspective and there were minimal changes in MO Medicaid reimbursement over the time 
period. 
Scaling Up Cost Savings to Approximate Savings for the Missouri Medicaid Populations 
To calculate the cost savings from a statewide “scale-up” of the program, we applied our 
CHOICE Project simulation model to individual data from the 2009-13 American Community 
Survey (ACS),23 which we limited to all Missouri women aged 18 to 45 who reported receipt of 
Medicaid or whose household income and uninsured status made them eligible for the MO-
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WHSP. This approach provides an estimation of the outcomes in a different population (i.e. 
Missouri women) controlling for age, race, ethnicity, and income as described above. ACS 
survey weights were used to scale the savings of Missouri ACS respondents to state population 
level savings. We used estimates of 20 to 40% LARC uptake to calculate a possible range of cost 
savings that might occur in a statewide scale-up.  
 
Results 
Estimated Contraceptive Mix for the CHOICE Project and Comparison Group 
Table 2 shows the contraceptive distribution for both groups. Women in the CHOICE 
Project were more likely to choose an IUD or implant than women in the comparison group, 
even after adjusting for baseline demographic differences between the groups. Women in the 
comparison group were more likely to choose OCPs, injectable contraception, condoms, or no 
contraceptive method.  
Estimated number of unintended pregnancies averted in the CHOICE Project 
 Table 3 shows the simulated unintended pregnancy and birth outcomes and cost savings 
for the CHOICE participants and comparison group. There were 475 unintended pregnancies 
among the CHOICE Project cohort and an estimated 1,402 unintended pregnancies in the 
comparison group for a total of 927 unintended pregnancies averted.  There were 247 unintended 
births in the CHOICE Project and an estimated 730 unintended births in the comparison group 
for 483 unintended births averted. The simulated CHOICE outcome of 247 unintended births 
was calibrated slightly to match the actual CHOICE outcome of 247 unintended births.   
Estimated Costs Savings Resulting from the CHOICE Project for Missouri Medicaid 
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 Table 3 also shows the estimated cost savings to Missouri Medicaid due to the CHOICE 
Project.  Not surprisingly, the CHOICE Project was associated with higher contraceptive costs 
compared to the comparison group, because more women in the CHOICE Project chose IUDs 
and implants. Most of these costs occurred early in the study period when most women were 
initiating IUDs and implants as shown in Figure 1. The pregnancy-related costs, however, are 
lower in the CHOICE Project than in the comparison group, both in absolute terms and the 
annual average, due to the higher number of pregnancies averted.  Because of the timeline of the 
CHOICE Project, approximately half of women were observed for two rather than three years.15 
For this reason, Table 3 reports an overall sum of costs and savings as well as an annualized 
average that is adjusted to account for the variation in follow-up time. Thus, total costs in the 
comparison group are estimated to be $12.2 million compared to $7.3 million for the CHOICE 
Project group, which is a 40.7% reduction in costs related to contraception, unintended 
pregnancy, and birth.  
Figure 1 compares monthly costs over time for the simulated CHOICE Project and 
comparison groups.  Higher up-front costs due to the use of IUDs and implants a lead to lower 
costs occurring during the two to three-year study follow-up period; we extended the comparison 
nine months beyond the study end to account for pregnancies in which conception occurred 
during study participation but the outcome (i.e. birth) did not occur until after the study ended, 
since these costs are also attributable to the study period.  
Estimated Cost Savings Scaled Up to Missouri Medicaid Statewide 
 ACS data show that 132,058 women of reproductive age received Missouri Medicaid 
annually. During 2011, the average enrollment in the Women’s Health Services Program was 
61,297.27 A scale-up of the CHOICE Project could save an estimated $79.7 million if 20% of 
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female, reproductive-age, Medicaid beneficiaries chose LARC, increasing to $156.8 million if 
40% chose LARC. The cost savings for the MO-WHSP range from an estimated $29.3 to $75.3 
million, respectively. Using ACS data, we also estimated that a total of 123,571 women were 
actually eligible for the MO-WHSP; if all these eligible women were to enroll, the estimated cost 
savings for this group would range from $59.0 to $151.9 million. These data are shown in Table 
4. 
 
Comment 
In this analysis, we found the CHOICE Project generated a $5.0 million cost savings for 
Missouri Medicaid due to unintended births averted among women who had Medicaid or who 
would be eligible for expanded Medicaid in the case of a pregnancy, a 41% reduction in costs for 
the cohort over the time period. The cost savings in our analysis are consistent with those 
estimated by other studies. A statewide initiative in Colorado serving about 50,000 women 
annually found that increased provision of LARC resulted in an estimated cost savings of 
approximately $52 million to the state Medicaid program. 24,25 A national study of publicly 
supported family planning services to 8.9 million women found a $10.5 billion cost savings due 
to unintended pregnancies averted.26 It is important to note that our cost savings analysis was 
conducted for a cohort of 5,000 women and estimated only the direct health costs of unintended 
pregnancies averted over the study period, not indirect economic and social costs affecting 
mothers and children. 
Strengths of this study include use of a comparison group of Missouri women seeking 
care at Title X health centers to estimate the contraceptive distribution in absence of the 
CHOICE Project.  We used the actual unintended pregnancy and birth rates from CHOICE to 
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inform the simulation and estimate the number of pregnancies averted by the CHOICE Project. 
The Monte Carlo simulation approach also allowed us to demonstrate the robustness of our 
findings to a range of assumptions. Lastly, we were able to obtain Missouri Medicaid level data 
for the costs of birth and first year of life to create a more precise estimate of costs associated 
with unintended birth, which is the largest contributor to pregnancy-related costs.  
There are some limitations to our study. First, women in both the CHOICE Project and 
the comparison group were presenting for contraceptive care and therefore may not reflect 
contraceptive use among the general population. Furthermore, women in the CHOICE Project 
may have self-selected into the study specifically because they desired LARC and, as result, may 
not be generalizable to other populations. However, a prior analysis comparing CHOICE 
participants’ with National Survey of Family Growth and Missouri Behavioral Risk Factor 
Surveillance System respondents found that while demographic and contraceptive characteristics 
did differ, the absolute differences were small.27 In addition, other programs have demonstrated 
LARC uptake substantially higher than the national estimates.24,28,29 Therefore, it is unlikely that 
the difference in LARC use between CHOICE participants and MO Title X patients is 
attributable mainly to selection bias. In addition, due to limited data for the MO Title X patients, 
we were only able to control for a small number of the demographic characteristics which may 
influence contraceptive preferences. Lastly, this analysis did not take into account contraceptive 
switching or discontinuation for any method other than IUDs and implants. Not capturing the 
costs associated with initiating a new method may underestimate contraceptive costs and 
overestimate the cost savings slightly. We also assumed that women who discontinued an IUD or 
implant, chose a new method based on the distribution of the comparison group. However, 
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women in the CHOICE Project group may have been more likely to choose another IUD or 
implant which would underestimate cost savings. 
Multiple barriers to LARC continue to exist, including requirements for preauthorization, 
multiple visits for initiation, insurance access, and cost.30,31 Furthermore, the U.S. federal 
government is actively working to weaken the contraceptive guarantee and the Title X 
program.32,33 However, there are also concerns that “promotion” of LARC may result in coercive 
practices.34,35 We emphasize that any interventions to increase access to LARC be patient-
centered, respect women’s autonomy, and include the full range of contraceptive options, while 
also removing barriers to care.  
Our results demonstrate that increased provision of IUDs and implants can reduce public 
healthcare spending. The potential cost savings of scaling up a model of care similar to the 
CHOICE Project are large; thus state Medicaid programs looking at budget priorities should 
focus on removal of barriers to all contraceptive methods. 
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Figure 1: Monthly Cost Expenditure over Contraceptive CHOICE Project Period.  
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Table 1. Demographic Characteristics of the Contraceptive CHOICE Project Participants and 
Missouri Title X Family Planning Patients. 
 Characteristic 
 
Contraceptive CHOICE 
Project 
 (n=5,061) 
MO Title X 
Family Planning 
Clinics,  
 (n=404,352) 
 
 
P 
value 
Age Category <0.0001 
  15-19 years 15.0% 1.4%  
  20-29 years 65.7% 55.0%  
  30-45 years 19.3% 43.7%  
Race <0.0001 
  Black 60.7% 29.3%  
  White 31.5% 68.3%  
  Other 7.7% 2.5%  
Ethnicity  
  Hispanic 6.4% 5.6% 0.015 
  Non-Hispanic 93.6% 94.4%  
Current Insurance  
  Uninsured (or unknown   
  coverage) 71.5% 72.8% 
0.033 
  Public insurance or family  
  planning waiver program 28.5% 27.2% 
 
Income <0.0001 
22  
  
  At or below 100% FPL 83.7% 70.0%  
  101%-200% of FPL 16.3% 30.0%  
Abbreviations: FPL, Federal Poverty Level 
Percentages may not add to 100% due to rounding. 
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Table 2. Contraceptive Distribution for the Contraceptive CHOICE Project and Comparison 
Group.  
Contraceptive 
Method 
Contraceptive 
CHOICE Project 
(n=5,061) 
Comparison 
Group a 
(n=5,061) 
Percentage 
Point 
Difference 
  N (%) N (%)   
Intrauterine device 2831 (55.9) 182 (3.6) + 52.3% 
Implant 1036 (20.5) 61 (1.2) + 19.3% 
Injectable 439 (8.7) 1731 (34.2) - 25.5% 
Oral contraceptive 
pills 406 (8.0) 2059 (40.7) - 32.7% 
Contraceptive patch 102 (2.0) 76 (1.5) + 0.5% 
Vaginal ring  246 (4.9)  142 (2.8) + 2.1% 
Natural family 
planning 0.0 10 (0.2) - 0.2% 
Male condom 0.0 577 (11.4) - 11.4% 
No method 0.0 172 (3.4) - 3.4% 
Other method 0.0 51 (1.0) - 1.0% 
Total 100 100 100 
a The contraceptive distribution for the simulated comparison group is based on MO Title X Family 
Planning Health Center data adjusted for age, race, ethnicity and income. 
Percentages may not add to 100% due to rounding. 
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Table 3. Comparison of Pregnancy and Cost Outcomes Between CHOICE Project and Simulated 
Comparison Group.  
  
Simulated 
CHOICE Project  
 (1) 
Simulated 
Comparison 
Group 
 (2) 
Difference 
(1-2) 
Number of Unintended Pregnancies 474.8 1401.7 -926.9 
  Unintended Pregnancy Rate 
  (per 1,000 reproductive age women) 
37.7 116.1   
Number of Unintended Births 246.9 729.6 -482.7 
  Unintended Birth Rate 
  (per 1,000 reproductive age women) 
19.6 60.4   
Total Cost $7,261,838  $12,246,296   -$4,984,458 
  Contraceptive Costs $4,019,056  $2,343,820  $1,675,236 
  Pregnancy-Related Costs $3,242,782  $9,902,476  -$6,659,694 
Annualized Cost $2,858,991  $4,821,376  -$1,962,385 
 
  
25  
  
Table 4. Estimated Cost Savings Associated with Statewide Scale Up of the Contraceptive 
CHOICE Project Model.  
 Percent Using a LARC Method 
 20% 30% 40% 
Women aged 18-45 who are current MO Medicaid beneficiaries (n=132,058)a 
Unintended pregnancies avoided 10,431 16,250 19,978 
Unintended births avoided 6,903 10,695 13,518 
Estimated cost savings, 2013$ $79,712,958 $123,788,762 $156,769,168 
Women enrolled in MO Women’s Health Services Program in 2011(n=61,297) 
Unintended pregnancies avoided 4,199 6,813 9,833 
Unintended births avoided 2,653 4,536 6,469 
Estimated cost savings, 2013$ $29,289,520 $52,563,031 $75,339,232 
Women aged 18-45 eligible for MO Women’s Health Services Program in 2011 (n=123,571)a 
Unintended pregnancies avoided 8,466 13,375 19,823 
Unintended births avoided 5,348 9,145 13,040 
Estimated cost savings, $2013 $59,045,880 $105,963,854 $151,879,280 
LARC, Long-Acting Reversible Contraceptive 
a Estimated using data from the 2009-13 Annual Community Survey 
 
Supplementary Materials: 
Sensitivity Analyses 
Sensitivity of our results to specific cost data used was a primary concern.  Although we 
reported our results using actual CHOICE Project costs and Missouri Medicaid reimbursement 
costs (simulated comparison group), we also ran a version of the model using average Medicaid 
costs reported in Laliberte et al,1 as an approximation of the mix of reimbursement rates 
(including 340b variations) at different health centers.  Using these cost data, in which the 
relative price of LARC compared to OCPs is much lower than in the cost data from the CHOICE 
Project, we found a total cost for study participants of $11.9 million in the comparison group and 
$6.3 million in the CHOICE case, for a cost savings of $5.6 million (46.7%). 
We also calculated CHOICE Project costs on the basis of Medicaid reimbursement rates, 
instead of the actual program costs associated with the staffing required for counseling and 
contraceptive provision.  Using Medicaid reimbursement rates for visit costs, we found a total 
cost of $12.2 million for study participants and $7.2 million for the comparison group, for a cost 
savings of $5.0 million (41.2%). 
The simulation also relied upon a combination of parameter choices taken from the 
literature but adjusted slightly to match the CHOICE population.  For example, data for Missouri 
overall show a 64% birth rate from unintended pregnancy, while only 52% of unintended 
pregnancies among CHOICE participants ended in live birth.  We experimented with an 
adjustment methodology to outcomes for unintended pregnancy factoring in the urban setting of 
CHOICE and found that this could explain about half of the difference.  To do so, we assumed 
that the state-level abortion rates, reported by Guttmacher, could be divided into urban and rural 
rates on a population-weighted basis.2  We estimated urban and rural populations of women of 
reproductive age using county-level Census data combined with Urban Influence Codes,3 which 
designate counties by urban/rural status.  We ran a regression to estimate a parameter that would 
capture the urban/rural differential, and we used the result to predict the abortion rate in an urban 
setting.  We thereby estimated that 58% of unintended pregnancies in urban areas of Missouri 
end in live birth, which approaches but does not equal the 52% in the CHOICE population.  The 
remaining difference may be due to unobserved characteristics specific to the CHOICE 
population, which does pose a limitation to the cost savings analysis for the CHOICE Project.  
However, we used the Missouri statewide values for the scaled up analysis.   
Finally, in order to capture women who use contraception inconsistently, we assumed 
that there was non-zero probability each month that a woman would experience a gap in any 
contraceptive method other than LARC methods.  The Guttmacher Institute reports that about 
23.5% of women using non-LARC methods have a gap in use while “at risk” of unintended 
pregnancy, and further that women at risk for unintended pregnancy experience gaps that 
average five months.4 The latter statistic includes gaps that occur while the woman is pregnant, 
so we assumed that the average would be lower for our population which excluded pregnant 
women.  We calibrated our “probability of a gap month” parameter so that the CHOICE 
outcomes would be matched more closely by the simulation model; the chosen value 
corresponds to an average gap of 0.9 months among women who experience a gap.  When 
scaling up the intervention to all Missouri women eligible for Medicaid family planning services 
and assuming a LARC uptake of 40%, we found that eliminating this probability (that is, making 
the strong assumption that Missouri women in general experience no gaps while using short-
acting contraception) reduces the combined expected savings from $308.6 million to $269.6 
million, which is therefore a lower bound for our prediction assuming a 40% rate of LARC 
uptake. 
Inputs for Cost Savings Estimates 
Table 1A. Cost of Contraceptive Methods and Initiation 
 Average Cost ($2013) 
Contraceptive Method Costs 
MO Medicaid Reimbursementa 
LARC $655.38 
OCP/Patch/Ring $200.31 
Injectable $192.47 
Condom $0 
No Method $0 
Laliberte et al 1  
LARC $437.67 
OCP/Patch/Ring $229.42 
Injectable $109.43 
Condom $0 
No Method $0 
Contraceptive Initiation Costs 
Contraceptive CHOICE Projectb  
LARC $136.53 
OCP/Patch/Ring $68.25 
Injectable $68.25 
Condom $0 
No Method $0 
Comparison Groupc 
LARC $120.96 
OCP/Patch/Ring $67.62 
Injectable $67.62 
Condom $0 
No Method $0 
a The average cost is weighted by the number of women choosing each method per year.  
b Annual salaries for a full-time nurse practitioner, a half-time registered nurse, and a full-time contraceptive 
counselor were averaged over the annual number of CHOICE Project enrollees over the study period to 
approximate costs depending on the year of enrollment. 
c Contraceptive initiation costs for the comparison group were estimated using Missouri Medicaid 
reimbursement rates based upon MOHealthNet fee schedule, available at  
https://apps.dss.mo.gov/fmsFeeSchedules/fsmain.aspx. The estimated cost of initiation of OCPs, patch, ring, 
and injectable contraception was the reimbursement amount for a new patient Level III office visit with a 
clinician. For LARC initiation costs, a weighted average of the reimbursement for a new visit based upon 
whether each type of IUD or the implant was chosen. 
LARC – long-acting reversible contraception; OCP – oral contraceptive pills; IUD – intrauterine device. 
  
Table 2A. Contraceptive Effectiveness and Unintended Pregnancy Outcome Probabilities 
 Probability 
Contraceptive Effectiveness5,6 
LARC5 0.986 
OCP/Patch/Ring5 0.928 
Injectable5 0.96 
Condom5 0.874 
No Method 6 0.15 
Unintended Pregnancy Outcome 
Birth2 0.64 
Miscarriage2 0.144 
Ectopic7 0.006 
Abortion, not covered by insurance2 0.207 
Abortion, covered by insurance8 0.003 
LARC – long-acting reversible contraception; OCP – oral contraceptive pills. 
 
 
 
 Table 3A, Cost of Unintended Pregnancy-Related Events 
Pregnancy Outcome Cost 
Birth9,10 a $13,801 
Miscarriage11 $604 
Ectopic11 $11,933 
Abortion, covered by insurance7 $1,874 
 a The average cost is weighted by the number of births per year. 
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